# Efficacy of Postoperative Adjuvant Chemotherapy for Stage II Colon Cancer With High Risk Factors(EPAC1)

> **NCT03199989** · PHASE3 · UNKNOWN · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 1254 (estimated)

## Conditions studied

- Adjuvant Chemotherapy

## Interventions

- **DRUG:** CapeOX（Capecitabine+Oxaliplatin）
- **OTHER:** Observation

## Key facts

- **NCT ID:** NCT03199989
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-06-01
- **Primary completion:** 2021-07-31
- **Final completion:** 2024-07-31
- **Target enrollment:** 1254 (ESTIMATED)
- **Last updated:** 2020-03-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03199989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03199989, "Efficacy of Postoperative Adjuvant Chemotherapy for Stage II Colon Cancer With High Risk Factors(EPAC1)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03199989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*